Drug · Small Molecule
Ifosfamide
CI-DRUG-00000680Explore in graph →CHEMBL1024 Approved
Regulatory
Approvals (8)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- Health Canada — Drug Product Database (DPD)
- Dataset
- Health Canada DPD
- Version
- dpd-2026-09-11
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- Open Government Licence – Canada (https://open.canada.ca/en/open-government-licence-canada)
- Run
- ING-HEALTHCANADADPD-20260911-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| CA Health Canada | — | Marketed in Canada as IFOSFAMIDE FOR INJECTION (DIN 02246565) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | withdrawnsource: Cancelled Post Marketsince Aug 29, 2024 | Apr 15, 2003 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as IFEX (DIN 02241357) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed | Mar 20, 2001 | health-canada-dpd |
| CA Health Canada | — | Marketed in Canada as IFEX (DIN 02241356) under ATC L01AA06 IFOSFAMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph. | approvedsource: Marketed |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 15 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 50 | 23 | 79 | 313 | 8 | CA, US | Aug 14, 1987 | 1990-05 |
| Malignant Testicular Neoplasm | Approved | Phase 2 | 0 | 0 | 0 | 2 | 1 | US | Aug 14, 1987 | Nov 5, 2007 |
| Non-Hodgkin Lymphoma | Phase4 | Phase 4 | 15 | 7 | 7 | 49 | 0 | — | — | 2002-07 |
| Leukemia | Phase4 | Phase 4 | 5 | 3 | 12 | 34 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (314)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07194044 | Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes(METTSEO) | recruiting |